These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

703 related articles for article (PubMed ID: 29562686)

  • 1. Profiling Prostate Cancer Therapeutic Resistance.
    Wade CA; Kyprianou N
    Int J Mol Sci; 2018 Mar; 19(3):. PubMed ID: 29562686
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cell death under epithelial-mesenchymal transition control in prostate cancer therapeutic response.
    Begemann D; Anastos H; Kyprianou N
    Int J Urol; 2018 Apr; 25(4):318-326. PubMed ID: 29345000
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epithelial-mesenchymal-transition regulators in prostate cancer: Androgens and beyond.
    Nakazawa M; Kyprianou N
    J Steroid Biochem Mol Biol; 2017 Feb; 166():84-90. PubMed ID: 27189666
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Crosstalk between epithelial-mesenchymal transition and castration resistance mediated by Twist1/AR signaling in prostate cancer.
    Shiota M; Itsumi M; Takeuchi A; Imada K; Yokomizo A; Kuruma H; Inokuchi J; Tatsugami K; Uchiumi T; Oda Y; Naito S
    Endocr Relat Cancer; 2015 Dec; 22(6):889-900. PubMed ID: 26311513
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Androgen receptor as a driver of therapeutic resistance in advanced prostate cancer.
    Kahn B; Collazo J; Kyprianou N
    Int J Biol Sci; 2014; 10(6):588-95. PubMed ID: 24948871
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-Coding RNAs Set a New Phenotypic Frontier in Prostate Cancer Metastasis and Resistance.
    Altschuler J; Stockert JA; Kyprianou N
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33672595
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Androgens modify therapeutic response to cabazitaxel in models of advanced prostate cancer.
    Begemann D; Wang Y; Yang W; Kyprianou N
    Prostate; 2020 Sep; 80(12):926-937. PubMed ID: 32542812
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Integrated Therapeutic Targeting of the Prostate Tumor Microenvironment.
    Livas L; Hasani S; Kyprianou N
    Adv Exp Med Biol; 2020; 1296():183-198. PubMed ID: 34185293
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epithelial mesenchymal transition (EMT) in prostate growth and tumor progression.
    Grant CM; Kyprianou N
    Transl Androl Urol; 2013 Sep; 2(3):202-211. PubMed ID: 25346895
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Achieving resistance specificity in prostate cancer.
    Wadhwa B; Dumbre R
    Chem Biol Interact; 2016 Dec; 260():243-247. PubMed ID: 27720870
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exploitation of the Androgen Receptor to Overcome Taxane Resistance in Advanced Prostate Cancer.
    Martin SK; Kyprianou N
    Adv Cancer Res; 2015; 127():123-58. PubMed ID: 26093899
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of androgens and the androgen receptor in epithelial-mesenchymal transition and invasion of prostate cancer cells.
    Zhu ML; Kyprianou N
    FASEB J; 2010 Mar; 24(3):769-77. PubMed ID: 19901020
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anoikis in phenotypic reprogramming of the prostate tumor microenvironment.
    Nepali PR; Kyprianou N
    Front Endocrinol (Lausanne); 2023; 14():1160267. PubMed ID: 37091854
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prostate tumor neuroendocrine differentiation via EMT: The road less traveled.
    Dicken H; Hensley PJ; Kyprianou N
    Asian J Urol; 2019 Jan; 6(1):82-90. PubMed ID: 30775251
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anoikis and EMT: Lethal "Liaisons" during Cancer Progression.
    Cao Z; Livas T; Kyprianou N
    Crit Rev Oncog; 2016; 21(3-4):155-168. PubMed ID: 27915969
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Extracellular vesicles released by mesenchymal-like prostate carcinoma cells modulate EMT state of recipient epithelial-like carcinoma cells through regulation of AR signaling.
    El-Sayed IY; Daher A; Destouches D; Firlej V; Kostallari E; Maillé P; Huet E; Haidar-Ahmad N; Jenster G; de la Taille A; Abou Merhi R; Terry S; Vacherot F
    Cancer Lett; 2017 Dec; 410():100-111. PubMed ID: 28935391
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emerging therapeutics targeting castration-resistant prostate cancer: the AR-mageddon of tumor epithelial-mesenchymal transition.
    Hendrix LN; Hamilton DA; Kyprianou N
    Expert Rev Endocrinol Metab; 2013 Jul; 8(4):403-416. PubMed ID: 30736155
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reversion of epithelial-mesenchymal transition by a novel agent DZ-50 via IGF binding protein-3 in prostate cancer cells.
    Cao Z; Koochekpour S; Strup SE; Kyprianou N
    Oncotarget; 2017 Oct; 8(45):78507-78519. PubMed ID: 29108245
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TGF-β receptor I inhibitor enhances response to enzalutamide in a pre-clinical model of advanced prostate cancer.
    Paller C; Pu H; Begemann DE; Wade CA; Hensley PJ; Kyprianou N
    Prostate; 2019 Jan; 79(1):31-43. PubMed ID: 30155899
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epithelial-mesenchymal transition in prostate cancer: an overview.
    Montanari M; Rossetti S; Cavaliere C; D'Aniello C; Malzone MG; Vanacore D; Di Franco R; La Mantia E; Iovane G; Piscitelli R; Muscariello R; Berretta M; Perdonà S; Muto P; Botti G; Bianchi AAM; Veneziani BM; Facchini G
    Oncotarget; 2017 May; 8(21):35376-35389. PubMed ID: 28430640
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.